Abstract
Renal cell carcinoma (RCC) is known to be a model of an immune-influenced malignancy. The immunobiology of RCC has three main immune cell types known to contribute to immunosuppression: T regulatory (Treg) cells, Type 2 T helper (Th2) cells, and myeloid derived suppressor cells. Sunitinib has rapidly revolutionized RCC treatment and is now a first-line standard of care for advanced RCC. Preliminary evidence reviewed here reveals that, in addition to antiangiogenic effects, sunitinib may have a direct or secondary effect on reversing the immunosuppressive environment by decreasing Treg cells and reversing the Th2 bias. Hypotheses for these observed effects and others are postulated based upon the mechanism of action. Current research is underway to further delineate the effect sunitinib has on the immune system and its mechanisms. Future therapeutics in RCC may include combination therapies that function collaboratively with sunitinib to harness an antitumor immune effect.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
